Dr. Narasimhan Mani joined Xiromed as Chief Executive Officer in February 2019 and brings with him with over 20 years of experience in both the scientific and business sides of the pharmaceutical industry. Prior to joining Xiromed, Dr. Mani spent several years in different multifunctional leadership roles, in the generic and branded product segments, across product development, manufacturing operations, portfolio management, strategic business development, and commercial operations. His vision and focus for Xiromed is to build a highly accomplished organization of experienced and talented professionals, offering high quality and value-added generic products over a broad range of dosage forms, technologies, and complex generics leading into strategic branded generics. Dr. Mani’s past industry positions include time at Elan Pharmaceuticals, Forest Laboratories, Par Pharmaceuticals, Johnson & Johnson, and Amneal Pharmaceuticals. Dr. Mani received his Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and an MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008.
Susan Stipic-Ryan joined Xiromed as Senior Director of Retail Sales in June of 2019. Bringing with her over 28 years of experience in the brand and generic pharmaceutical industries, she has held positions of increasing responsibility and continued growth within both the brand and generic sides of the pharmaceutical industry throughout her career. Susan held previous roles at Bristol-Myers Squibb, Kremers Urban Inc., and Amneal Pharmaceuticals as Director of National Accounts. Susan’s focus and expertise lie within the retail space. Susan has been an integral part of helping to build companies from the ground up working in sales, customer strategies, and successfully launching 70+ products during her career. Susan holds her Bachelor of Arts, Communications from Seattle Pacific University.
Santhanakrishnan Srinivasan, Ph.D. is a healthcare professional with over 15 years of experience in formulation development, manufacturing operations, regulatory affairs, and clinical research. As Vice President, Technical Strategy and Complex Products at Xiromed, Santhanakrishnan is responsible for leading the product development of Xiromed’s pipeline products and technical due-diligence of technologies and products in-licensed from partners across all dosage forms with a special emphasis on complex whitespace generics and drug-device combination products. He held positions of increasing responsibility in Pharmaceutical Product Development, R&D Operations, and R&D project Management at Dr. Reddy’s Laboratories and Amneal Pharmaceuticals. Dr. Srinivasan is an active member of numerous pharmaceutical associations and is also a member of the International and Scientific Advisory Board of Society for Pharmaceutical Dissolution Sciences – India.
Rocco Mastrodomenico, Senior Director of Finance, has over 20 years of business experience within the Healthcare and Financial Services industries. Rocco began his career at Deloitte & Touche as an auditor and has held various positions of increasing responsibility in both public accounting and private industry. Rocco worked for Exeltis USA Inc. as Controller and performed post-acquisition integration of all finance functions and was responsible for leading a team through monthly close, annual budgets and financial statements. In 2018 he joined Rising Pharmaceuticals as Director of Finance, where he implemented systems and process improvements, as well as, oversee the day to day functions of the accounting area. Rocco holds his Bachelor of Science degree in Accounting from Babson College and is a Certified Public Accountant.
Donna Genova joined Xiromed as Vice President Sales & Commercial Operations and brings with her over 25 years of experience in both the generic and branded side of the pharmaceutical industry. Prior to Xiromed, she most recently held pivotal positions in areas of Institutional and Retail Sales Operations including contracts, pricing, customer strategy, product strategy, sales budgets and forecasts, and new product launches. Earlier in her career, she held positions in financial planning & analysis, budgeting, and sales force effectiveness. Donna’s past industry positions include her tenure at Amneal Pharmaceuticals, Kremers Urban Pharmaceuticals, Lannett Pharmaceuticals, and Bristol Myers Squibb & Sons. Donna holds her Bachelor of Arts degree in Economics and Finance from Douglass College, Rutgers University, and her Masters of Business Administration degree in Finance from Rutgers University Graduate School of Management.
Lisa DiGrazia, Senior Director of Business Strategy & Portfolio, joined Xiromed with experience as a healthcare professional in a hospital, retail, and pharmaceutical industry settings. Prior to Xiromed, Lisa worked as a Clinical Oncology Pharmacy Specialist at Rush University Medical Center, where she provided direct patient care and comprehensive clinical services, including overseeing clinical trials and pharmacy policy development. She then joined Amneal Pharmaceuticals to help build a strong and differentiated pipeline of products and support the commercial institutional team with their launch of injectables and biosimilars. Lisa received a PharmD from Midwestern University, Chicago College of Pharmacy. She then completed her internal medicine residency at Rush University Medical Center and her oncology residency at Memorial Sloan Kettering Cancer Center. Her board certifications include Board-Certified Oncology Pharmacist (BCOP) and Board Certified Pharmacotherapy Specialist (BCPS).
David Hernandez, Vice President of Regulatory Affairs and US R&D Operations, has spent the last 15 years with a specific focus in complex, first to market, generic drugs. As one of Xiromed’s founding members, David supports the execution, development, and approval of Xiromed’s R&D pipeline as well as new product launch and business development. Prior to joining Xiromed in 2015, David led Alvogen’s regulatory strategy and First-to-File generics portfolio. He has also worked in Regulatory Affairs, Compliance, and Quality for Watson (Teva), Nycomed US (Sandoz), and Barr Labs (Teva). David holds a Bachelor's degree in Biology from Purchase College and a Master’s Degree in Regulatory Affairs from Northeastern University.
Steven Esposito, Vice President of Institutional Sales has concentrated his career within the institutional space for over 20 years. He has worked with some of the most successful new-to-market companies, and was instrumental in taking leadership roles within the sales/marketing and strategic planning areas of business. Throughout his career, Steven has created growth among these companies from their beginnings into some of the most successful organizations within the healthcare arena. With his knowledge of the industry, Steven has always been pivotal in implementing sales protocols and strategy for product placement and contracting which allows him to stay ahead of market trends and conditions. Steven holds a BA from Northeastern Illinois University.
Ramandeep Singh Jaj is a sales and business development professional with 19 years of experience in the pharmaceutical & healthcare sector. He has a proven record of establishing markets across North America, Europe, Latam and SE Asia. He joined Chemo, one of the group companies of Insud Pharma, in January 2012 and was a key member establishing Chemo’s North American operations. He currently leads all business development activities for Xiromed as part of his responsibilities. His specialties include P&L Accountability, Corporate strategy, Sales/margin Analysis, global business negotiations, budget planning & strategic alliance management in both the API & Finished Dosage forms businesses. His past experience includes key positions at Shasun, Orchid Pharma & Piramal Healthcare.